Biotech firm 'will not charge'NHS for breast cancer tests
By Lynn Eaton2000-09-07T00:00:00
Scottish biotechnology firm Rosgen has announced that it does not plan to charge the NHS for carrying out tests for mutations in two genes linked to breast cancer.
You need to be signed in to read more
Subscribe for unlimited access
With a HSJ subscription you’ll unlock:
- All of HSJ.co.uk and our HSJ mobile app
- News and insight on all areas of public funded healthcare
- Expert commentary, insight and analysis from industry leaders
- 9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics
HSJ is part of Wilmington Healthcare Limited, Beechwood House, 2-3 Commercial Way, Christy Close, Southfields, Essex, SS15 6EF. Company number 2530185. c/o Wilmington plc, 5th Floor, 10 Whitechapel High Street, London E1 8QS. Registered in England and Wales. Company registration 30158470
Site powered by Webvision Cloud